


Data sharing experiences from the publicly accessible WHO TB-IPD platform

Stella Maris Fabiane¹, Assica Hakiman¹, Angela Crook¹, Samuel Schumacher², Fuad Mirzayev², Lele Rangaka^{1,3}, Ruth Goodall¹ ¹MRC CTU at UCL, London, UK, ²WHO Geneva, Switzerland, ³Institute for Global Health, UCL, London, UK

INTRODUCTION

"...increase the knowledge base for normative guidance on optimal treatment for drug-resistant



tuberculosis..."


- WHO call for new more flexible IPD platform (Mar2021)
- Clear link of IPD with WHO to allow regular public calls for data, and flexibility in systematic review team selection, for GDG
- University College London selected as Data Curator

The **purpose** of the TB-IPD is to facilitate:

- pooling of individual participant data from researchers, local or national databases in the context of TB treatment
- policy update, development and public health research.
- informing future treatment guidelines
- expanding the knowledge and understanding of TB globally

The original project is being expanded to include:


- clinical trials e.g. STREAM
- drug-sensitive (DS) TB
- paediatric and pregnancy data



ANONYMISATION

The TB-IPD Platform houses individual participant data which are **effectively** anonymised:

- in TB-IPD:
 - Overtly personal data removed
 - Held in Data Safe Haven (highly secure)
- when released to researchers:



DATA SHARING AGREEMENTS

- the most challenging part of this process
- taken over a year to finalise an agreement acceptable to all stakeholders (academia, pharma, national treatment programs)
- need to be generic but satisfy all parties due to the large number of datasets included, aim to have one DSA used by all
- covers confidentiality; data sharing principles, including use, storage, deletion; liability; ethics; publication and acknowledgement.

ISSUES

- Country specific interpretation of GDPR within Europe
 - differing definitions of anonymisation
- Sharing data with profit-making organisations is a sensitive/difficult topic for many data contributors – definition of non-commercial use.

- No access to keys
- Higher risk data (e.g. DOB) removed
- Location information restricted
- Treatment as intervals, not dates
- Assurances on security
- Limited named access
- Written assurances not to attempt reidentification

GOVERNANCE

Data Access Committee: responsible for reviewing and accepting/rejecting applications for data access.

Anneke Hesseling (South Africa), Salmaan Keshavjee (USA), Norbert Ndjeka (South Africa), Ezio Távora dos Santos Filho (Brazil), Bern-Thomas Nyang'wa (The Netherlands), Carla Winston (USA), WHO representative

Steering Committee: responsible for oversight and coordination of the TB-IPD Platform (currently WHO and UCL)

CURRENTLY

DAC has met 4 times and reviewed 5 requests for




 Contributors may want to change legal jurisdictions from England & Wales.

DATA ACCESS AGREEMENTS

- DAC has complete decision-making control regarding data availability to analysts.
- Data access allowed exclusively for approved projects; no other purposes permitted.
- Only necessary datasets are provided for analyses.
- Only named delegates are allowed to download the data.
- Security of data environment at analyst's side must be suitable.

N datasets	62
historical	50 (n = 36,248)
paediatric	8 (n = 939)
trials	4 (n = 4041)

Status of Historical Datasets in TB-IPD Platform



data.

Data has been shared with

4 Data Requestors; leading to 1 publication to date.

Acknowledgements

Neil Stoker (UCL-TB), Alex Potts (UCL Data Protection) UCL Legal Services, Andy Duncan, Trish Greenan, Lydia Walker Dick Menzies, Jonathon Campbell (McGill) Greg Fox, Tasnim Hassan (Sydney) Tony Garcia-Prats, Anneke **Smarter Studies** Hesseling **Global Impact** (Stellenbosch) **Better Health**